All Online

1 - 2 of 2 results


Active filters

Diabetes Mellitus, Type 1
insulin needle vials and syringe

Type 2 diabetes is marked by progressive beta cell dysfunction requiring progressive pharmacological therapy to maintain glucose control. In this Clinical Coffee Break, Dr. Andrew Ahmann of Oregon Health and Science University, and Dr. Dace Trence of the University of Washington Medical Center in Seattle, discuss why providers would consider using basal insulin early in the progression of treatment. Their discussion also emphasizes how to address the potential barriers to insulin therapy, including hypoglycemia, in order to safely optimize this highly effective therapy. Lastly, they highlight how new ultralong-acting basal insulin products may offer more consistent 24 hour coverage and reduced risk for hypoglycemia.